← Back to Search

Repeat Surgery for Recurrent Glioblastoma

N/A
Recruiting
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Previously histologically confirmed and surgically resected Glioblastoma
Previous craniotomy for open tumor resection (needle biopsies alone do not count as resection)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up follow-up for 5 years or until death
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if performing another surgery to remove a brain tumor can help patients with Glioblastoma live longer and spend more time at home instead of in medical facilities.

Who is the study for?
This trial is for adults over 18 with recurrent Glioblastoma (GBM) who've had it surgically removed before. Candidates should be considered by their surgeon to potentially benefit in quality of life from another surgery. Those unable to give informed consent are excluded.
What is being tested?
The study tests the effectiveness of repeat surgical resection on patients with recurrent GBM, aiming to see if a second surgery can extend overall survival and improve time spent out of hospitals or care facilities without extra risks beyond standard care.
What are the potential side effects?
Since the intervention involves routine surgical procedures, potential side effects include typical surgical risks such as infection, bleeding, neurological deficits depending on tumor location, and general anesthesia complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My glioblastoma was confirmed by a biopsy and has been surgically removed.
Select...
I have had brain surgery to remove a tumor.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~follow-up for 5 years or until death
This trial's timeline: 3 weeks for screening, Varies for treatment, and follow-up for 5 years or until death for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Length of Overall Survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Repeat Surgical ResectionExperimental Treatment1 Intervention
Standard surgical operative management according to local practices.
Group II: Management Without Re-operationActive Control1 Intervention
Non-surgical management with standard care according to local practices.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The primary treatments for Glioblastoma include surgical resection, radiation therapy, and chemotherapy. Surgical resection aims to remove as much of the tumor as possible, which can alleviate symptoms and improve survival. Radiation therapy uses high-energy beams to kill cancer cells and shrink tumors, targeting residual cells post-surgery. Chemotherapy, often with the drug temozolomide, works by damaging the DNA of cancer cells, preventing their replication. For recurrent GBM, repeat surgery (re-resection) may be considered to further reduce tumor burden and potentially improve survival and quality of life. These treatments are crucial as they address the aggressive nature of GBM, aiming to prolong survival and maintain neurological function.

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
942 Previous Clinical Trials
434,159 Total Patients Enrolled

Media Library

Repeat Surgical Management of Recurrent GBM Clinical Trial Eligibility Overview. Trial Name: NCT04838782 — N/A
Brain Cancer Research Study Groups: Repeat Surgical Resection, Management Without Re-operation
Brain Cancer Clinical Trial 2023: Repeat Surgical Management of Recurrent GBM Highlights & Side Effects. Trial Name: NCT04838782 — N/A
Repeat Surgical Management of Recurrent GBM 2023 Treatment Timeline for Medical Study. Trial Name: NCT04838782 — N/A
~150 spots leftby Jan 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top